Back to Search
MICHAEL MELTON, MD
MD
Radiation Oncology Physician
NPI: 1306469648IndividualAccepts Medicare
Specialties, Licenses & Credentials
Radiation Oncology PhysicianPrimary
Radiology — Radiation Oncology
Code: 2085R0001X
1306469648(AL)
CMS Specialties
PrimaryRADIATION ONCOLOGY
Education
UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE
Class of 2022
Research & Publications (20)
A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.
PMID 19168710·J Pharmacol Exp Ther·2009
7-preclinical
Identification and validation of vertebral compression fractures using administrative claims data.
PMID 19106733·Med Care·2009
4-observational
Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study.
PMID 18797812·Osteoporos Int·2009
4-observational
Inhibition of native and recombinant nicotinic acetylcholine receptors by the myristoylated alanine-rich C kinase substrate peptide.
PMID 18812491·J Pharmacol Exp Ther·2008
7-preclinical
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
PMID 18324951·Int J Clin Pract·2008
4-observational
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
PMID 17594775·Curr Med Res Opin·2007
4-observational
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.
PMID 17389291·Arch Intern Med·2007
2-rct
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
PMID 17163237·Clin Drug Investig·2006
4-observational
The C-terminal zinc finger of UvrA does not bind DNA directly but regulates damage-specific DNA binding.
PMID 16829526·J Biol Chem·2006
8-other
Pharmacy access to emergency contraception in California.
PMID 16554271·Perspect Sex Reprod Health·2006
8-other
Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by beta-amyloid1-42 peptide.
PMID 16055943·J Mol Neurosci·2005
7-preclinical
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
PMID 15207890·Maturitas·2004
3-trial
Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
PMID 15140336·Curr Med Res Opin·2004
3-trial
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
PMID 15049885·J Intern Med·2004
3-trial
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
PMID 12695269·Arch Intern Med·2003
3-trial
Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein.
PMID 12747787·J Med Chem·2003
7-preclinical
Performance of risk indices for identifying low bone density in postmenopausal women.
PMID 12108600·Mayo Clin Proc·2002
8-other
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
PMID 12020142·Ann Intern Med·2002
3-trial
Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein.
PMID 12190312·J Med Chem·2002
7-preclinical
The effects of dexamethasone on bone fusion in an experimental model of posterolateral lumbar spinal arthrodesis.
PMID 11147871·J Neurosurg·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 865 RESEARCH PKWY
OKLAHOMA CITY, OK 73104 - Phone
- (405) 271-4000
Quick Facts
- NPI
- 1306469648
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile